BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703)

Authors :: Takako Eguchi Nakajima
Daisuke Kotani
Hiroko Bando
Taito Esaki
Nozomu Fuse
Yasuo Komatsu
T. Satoh
Tomohiro Nishina
Takayuki Yoshino
Kensei Yamaguchi
Hiromichi Ebi
S. Sakamoto
A. Ohtsu
Toshiki Masuishi
Sachiyo Nomura
A. Sato
Satoshi Fujii
M. Yonemura
S. Iida
S. Matsuda
Source :: Annals of Oncology. 29:viii201-viii202
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Tools